Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 7/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 3/20 | 0.41 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propionic Acid SCHEMBL4155591 | 0.91 | BRD4 (0.50) | BRD4ESR1POLBJAK1HIF1A | |
| Propionic Acid SCHEMBL4158106 | 0.91 | BRD4 (0.60) | BRD4HTR6 | |
| Propionic Acid SCHEMBL4169897 | 0.90 | BRD4 (0.59) | BRD4ESR1HIF1AHTR6PKM | |
| Propionic Acid SCHEMBL4155599 | 0.90 | BRD4 (0.49) | BRD4ESR1POLBHTR6MEN1 | |
| Propionic Acid SCHEMBL4162384 | 0.90 | MAPT (0.49) | BRD4MEN1RAB9AKMT2A | |
| Propionic Acid SCHEMBL4162543 | 0.90 | MEN1 (0.54) | BRD4MEN1RAB9AKMT2APKM | |
| Propionic Acid SCHEMBL4162655 | 0.89 | BRD4 (0.62) | BRD4POLBHIF1AMEN1KMT2A | |
| Propionic Acid SCHEMBL4164250 | 0.89 | BRD4 (0.62) | BRD4ESR1POLBHTR6MEN1 | |
| Propionic Acid SCHEMBL4162569 | 0.88 | MAPT (0.51) | BRD4HIF1AMEN1KMT2APKM | |
| Propionic Acid SCHEMBL4157756 | 0.86 | BRD4 (0.63) | BRD4HIF1AHTR6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | claimed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | claimed |
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | BRD4 545/4885ESR1 2823/4885POLB 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.